4.4 Review

Management of Parkinson's Disease 20 Years from Now: Towards Digital Health Pathways

期刊

JOURNAL OF PARKINSONS DISEASE
卷 8, 期 -, 页码 S85-S94

出版社

IOS PRESS
DOI: 10.3233/JPD-181519

关键词

Parkinson's disease; management; treatment; digital pathways; innovation; healthcare

资金

  1. EIT-Health grant MoveIT
  2. Bavarian Ministry of Economics (FallRiskPD)
  3. EIT-Health (MoveIT)
  4. EIT-Digital (Vital@Home)
  5. Fraunhofer Attract grant (DHPs)
  6. Fonds National de Recherche de Luxembourg (FNR
  7. PEARL) [FNR/P13/6682797]
  8. Fonds National de Recherche de Luxembourg (FNR
  9. NCER-PD) [FNR/NCER13/BM/11264123]
  10. European Union's Horizon2020 research and innovation program (WIDESPREAD
  11. CENTRE-PD) [692320]
  12. Parkinson's Foundation

向作者/读者索取更多资源

Current best medical treatment for patients with Parkinson's disease (PD) involves a medical professional who applies state-of-the-art knowledge of diagnostics and treatment-as derived from cohort studies and clinical trials-to the healthcare process of individual patients. Thus, the much-needed personalization of medicine depends on the abilities, experience and intuition of medical professionals to adjust group-based knowledge to individual decision making. Within 20 years from now, such personal clinical decisions will be largely supported by digital means, also defining a new ecosystem of healthcare often referred to as digital medicine. We expect that the next phase of digitalization will include newdigital health pathways: data-driven personalized decision support that is based on a combination of multimodal data sources, including evidence-based medical knowledge (e.g., clinical guidelines), personal disease profiles (including genetic determinants of disease progression and treatment response), insights into individual disease trajectories (thereby defining subgroups of patients) and individual patients' needs. Here, we illustrate the potential of this development by sketching the contours of a digitally supported care pathway for gait disability and falls. Such digital health pathways will support the introduction of personalized medicine for PD patients, allowing patients to benefit optimally from individually tailored treatments. This should result in a better quality of life for patients and lower costs for society.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Medicine, Research & Experimental

Deep Brain Stimulation and Levodopa Affect Gait Variability in Parkinson Disease Differently

Zi H. Su, Salil Patel, Bronwyn Gavine, Tim Buchanan, Marko Bogdanovic, Nagaraja Sarangmat, Alexander L. Green, Bastiaan R. Bloem, James J. FitzGerald, Chrystalina A. Antoniades

Summary: This study compared the effects of dopaminergic medication and subthalamic nucleus deep brain stimulation (STN DBS) on gait variability in Parkinson disease patients. The results showed that STN DBS reduced short-term variability in lower limb gait parameters, while medication did not have this effect. In addition, STN DBS had no effect on arm swing and trunk motion variability, while medication increased them.

NEUROMODULATION (2023)

Article Clinical Neurology

Levodopa Response in Patients With Early Parkinson Disease Further Observations of the LEAP Study

Henrieke L. Frequin, Jason Schouten, Constant V. M. Verschuur, Sven R. Suwijn, Judith A. Boel, Bart Post, Bastiaan R. Bloem, Johannes J. van Hilten, Teus van Laar, Gerrit Tissingh, Alexander G. Munts, Joke M. Dijk, Gunther Deuschl, Anthony Lang, Marcel G. W. Dijkgraaf, Rob J. de Haan, Rob M. A. de Bie

Summary: The study found that levodopa had similar effects on bradykinesia, rigidity, and tremor in patients with early Parkinson's disease. The improvements in symptoms were larger at 22 weeks compared to 4 weeks. At 80 weeks, fewer patients in the early-start group experienced motor response fluctuations.

NEUROLOGY (2023)

Article Clinical Neurology

Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort

Eva-Juliane Vollstedt, Susen Schaake, Katja Lohmann, Shalini Padmanabhan, Alexis Brice, Suzanne Lesage, Christelle Tesson, Marie Vidailhet, Isabel Wurster, Faycel Hentati, Anat Mirelman, Nir Giladi, Karen Marder, Cheryl Waters, Stanley Fahn, Meike Kasten, Norbert Bruggemann, Max Borsche, Tatiana Foroud, Eduardo Tolosa, Alicia Garrido, Grazia Annesi, Monica Gagliardi, Maria Bozi, Leonidas Stefanis, Joaquim J. Ferreira, Leonor Correia Guedes, Micol Avenali, Simona Petrucci, Lorraine Clark, Ekaterina Y. Fedotova, Natalya Y. Abramycheva, Victoria Alvarez, Manuel Menendez-Gonzalez, Silvia Jesus Maestre, Pilar Gomez-Garre, Pablo Mir, Andrea Carmine Belin, Caroline Ran, Chin-Hsien Lin, Ming-Che Kuo, David Crosiers, Zbigniew K. Wszolek, Owen A. Ross, Joseph Jankovic, Kenya Nishioka, Manabu Funayama, Jordi Clarimon, Caroline H. Williams-Gray, Marta Camacho, Mario Cornejo-Olivas, Luis Torres-Ramirez, Yih-Ru Wu, Guey-Jen Lee-Chen, Ana Morgadinho, Teeratorn Pulkes, Pichet Termsarasab, Daniela Berg, Gregor Kuhlenbaumer, Andrea A. Kuhn, Friederike Borngraeber, Giuseppe de Michele, Anna De Rosa, Alexander Zimprich, Andreas Puschmann, George D. Mellick, Jolanta Dorszewska, Jonathan Carr, Rosangela Ferese, Stefano Gambardella, Bruce Chase, Katerina Markopoulou, Wataru Satake, Tatsushi Toda, Malco Rossi, Marcelo Merello, Timothy Lynch, Diana A. Olszewska, Shen-Yang Lim, Azlina Ahmad-Annuar, Ai Huey Tan, Bashayer Al-Mubarak, Hasmet Hanagasi, Dariusz Koziorowski, Sibel Ertan, Gencer Genc, Patricia de Carvalho Aguiar, Melinda Barkhuizen, Marcia M. G. Pimentel, Rachel Saunders-Pullman, Bart van de Warrenburg, Susan Bressman, Mathias Toft, Silke Appel-Cresswell, Anthony E. Lang, Matej Skorvanek, Agnita J. W. Boon, Rejko Kruger, Esther M. Sammler, Vitor Tumas, Bao-Rong Zhang, Gaetan Garraux, Sun Ju Chung, Yun Joong Kim, Juliane Winkelmann, Carolyn M. Sue, Eng-King Tan, Joana Damasio, Peter Klivenyi, Vladimir S. Kostic, David Arkadir, Mika Martikainen, Vanderci Borges, Jens Michael Hertz, Laura Brighina, Mariana Spitz, Oksana Suchowersky, Olaf Riess, Parimal Das, Brit Mollenhauer, Emilia M. Gatto, Maria Skaalum Petersen, Nobutaka Hattori, Ruey-Meei Wu, Sergey N. Illarioshkin, Enza Maria Valente, Jan O. Aasly, Anna Aasly, Roy N. Alcalay, Avner Thaler, Matthew J. Farrer, Kathrin Brockmann, Jean-Christophe Corvol, Christine Klein

Summary: Through a worldwide online survey, we established an international cohort of individuals with PD-linked variants, providing harmonized and quality-controlled clinical and genetic data for each participant and promoting collaboration among researchers in the field of monogenic PD.

MOVEMENT DISORDERS (2023)

Editorial Material Neurosciences

The Journal of Parkinson's Disease Takes the Open Road

Bastiaan R. Bloem, Lorraine V. Kalia

JOURNAL OF PARKINSONS DISEASE (2023)

Editorial Material Clinical Neurology

Mask On, Mask Off: Subclinical Parkinson?s Disease Unveiled by COVID-19

Milan Beckers, Bastiaan R. Bloem, Rick C. Helmich

JOURNAL OF MOVEMENT DISORDERS (2023)

Article Biochemistry & Molecular Biology

Propagative α-synuclein seeds as serum biomarkers for synucleinopathies

Ayami Okuzumi, Taku Hatano, Gen Matsumoto, Shuko Nojiri, Shin-ichi Ueno, Yoko Imamichi-Tatano, Haruka Kimura, Soichiro Kakuta, Akihide Kondo, Takeshi Fukuhara, Yuanzhe Li, Manabu Funayama, Shinji Saiki, Daisuke Taniguchi, Taiji Tsunemi, Deborah McIntyre, Jean-Jacques Gerardy, Michel Mittelbronn, Rejko Kruger, Yasuo Uchiyama, Nobuyuki Nukina, Nobutaka Hattori

Summary: A modified assay system (IP/RT-QuIC) has been developed to detect pathogenic alpha-synuclein seeds in the serum of individuals with synucleinopathies. The system showed high diagnostic performance for differentiating Parkinson's disease and multiple system atrophy from controls.

NATURE MEDICINE (2023)

Article Cell & Tissue Engineering

p Generation of two induced pluripotent stem cell lines and the corresponding isogenic controls from Parkinson?s disease patients carrying the heterozygous mutations c.1290A > G (p.T351A) or c.2067A > G (p. T610A) in the RHOT1 gene encoding Miro1

Axel Chemla, Giuseppe Arena, Claudia Saraiva, Clara Berenguer-Escuder, Dajana Grossmann, Anne Grunewald, Christine Klein, Philip Seibler, Jens C. Schwamborn, Rejko Kruger

Summary: In this study, two Parkinson's disease patients' primary skin fibroblasts carrying distinct heterozygous mutations in the RHOT1 gene encoding Miro1 were reprogrammed into induced pluripotent stem cells (iPSCs) using episomal reprogramming. Isogenic gene-corrected lines were generated using CRISPR/Cas9 technology. Both isogenic pairs were comprehensively characterized and quality assured to study the Miro1-related molecular mechanisms underlying neurodegeneration in iPSC-derived neuronal models.

STEM CELL RESEARCH (2023)

Article Neurosciences

Device-Aided Therapies in Parkinson's Disease-Results from the German Care4PD Study

Odette Fruendt, Anne-Marie Hanff, Annika Moehl, Tobias Mai, Christiane Kirchner, Ali Amouzandeh, Carsten Buhmann, Rejko Kruger, Martin Suedmeyer

Summary: Data on the use of device-aided therapies (DATs) in people with Parkinson's disease (PwP) are scarce. German DAT application rate is rather low, indicating a need for precise identification of symptoms and implementation in future treatment strategies.

BRAIN SCIENCES (2023)

Article Neurosciences

Two-year clinical progression in focal and diffuse subtypes of Parkinson's disease

Martin E. Johansson, Nina M. van Lier, Roy P. C. Kessels, Bastiaan R. Bloem, Rick C. Helmich

Summary: Heterogeneity in Parkinson's disease (PD) makes it difficult to understand the disease and develop treatments. Stratifying patients into subtypes based on clinical characteristics may help overcome this challenge. A recent study classified de novo PD patients into three subtypes and found that the diffuse-malignant subtype had more severe symptoms and faster progression compared to the mild-motor predominant subtype. These findings suggest different pathophysiological mechanisms underlie distinct PD subtypes.

NPJ PARKINSONS DISEASE (2023)

Review Clinical Neurology

Exercise Made Accessible: the Merits of Community-Based Programs for Persons with Parkinson's Disease

Anneli Langbroek-Amersfoort, Sabine Schootemeijer, Lars Bouten, Bastiaan R. Bloem, Nienke M. De Vries

Summary: There is increasing evidence supporting the positive effects of community-based exercise for individuals with Parkinson's disease. However, the studies on this topic vary greatly in terms of exercise types, study designs, and outcome measures. While this review acknowledges the feasibility and potential benefits of community-based exercise, it also emphasizes the need for improvement in the overall quality of these studies.

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2023)

Article Clinical Neurology

Validation of a Parkinson's disease questionnaire-39-based functional mobility composite score (FMCS) in people with Parkinson's disease

Anne-Marie Hanff, Christopher McCrum, Armin Rauschenberger, Gloria A. Aguayo, Maurice P. Zeegers, Anja K. Leist, Rejko Kruger

Summary: This study aimed to validate the algorithm calculating the Functional Mobility Composite Score (FMCS) based on the Parkinson's Disease Questionnaire-39 (PDQ-39). The results showed that the FMCS has good convergent and discriminative validity, making it a reliable measure for assessing functional mobility through patient reports in people with Parkinson's disease.

PARKINSONISM & RELATED DISORDERS (2023)

Review Clinical Neurology

Predictors and Pathophysiology of Axial Postural Abnormalities in Parkinsonism: A Scoping Review

Carlo Alberto Artusi, Christian Geroin, Jorik Nonnekes, Camila Aquino, Divyani Garg, Marian L. Dale, Darbe Schlosser, Yijie Lai, Mohammad Al-Wardat, Mehri Salari, Robin Wolke, Valery Tsinda Labou, Gabriele Imbalzano, Serena Camozzi, Marcelo Merello, Bastiaan R. Bloem, Tamine Capato, Ruth Djaldetti, Karen Doherty, Alfonso Fasano, Houyam Tibar, Leonardo Lopiano, Nils G. Margraf, Caroline Moreau, Yoshikazu Ugawa, Roongroj Bhidayasiri, Michele Tinazzi

Summary: Axial postural abnormalities are common in patients with Parkinson's disease and atypical parkinsonism, and have a significant impact on the patients' quality of life. However, there is limited understanding of the pathophysiology and clinical predictors of these symptoms, highlighting the need for further research in this area.

MOVEMENT DISORDERS CLINICAL PRACTICE (2023)

Editorial Material Clinical Neurology

If you only have 7 minutes, make them count!

Tessa F. Peerbolte, Rozanne J. A. van Diggelen, Marjan J. Meinders, Bastiaan R. Bloem, Sanne W. van den Berg

PRACTICAL NEUROLOGY (2023)

Letter Clinical Neurology

Reply to: From Unsolicited Medical Opinions to Viral Medical Discussions: Is Sharing Caring?

Rui Araujo, Jos J. Kole, Joaquim J. Ferreira, Bastiaan R. Bloem

MOVEMENT DISORDERS CLINICAL PRACTICE (2023)

Article Clinical Neurology

A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease

Francisco Cardoso, Christopher G. Goetz, Tiago A. Mestre, Cristina Sampaio, Charles H. Adler, Daniela Berg, Bastiaan R. Bloem, David J. Burn, Michael S. Fitts, Thomas Gasser, Christine Klein, Marina A. J. de Tijssen, Anthony E. Lang, Shen-Yang Lim, Irene Litvan, Wassilios G. Meissner, Brit Mollenhauer, Njideka Okubadejo, Michael S. Okun, Ronald B. Postuma, Per Svenningsson, Louis C. S. Tan, Taiji Tsunemi, Sarah Wahlstrom-Helgren, Oscar S. Gershanik, Victor S. C. Fung, Claudia Trenkwalder

MOVEMENT DISORDERS (2023)

暂无数据